ここから本文です

FDA Approves EYLEA® (aflibercept) Injection for All Stages of Diabetic Retinopathy!!!!!!!

TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ --
-EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness
-Diabetic retinopathy is the leading cause of blindness among working-aged American adults

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness.